The ability of ESSH to modulate the expression of Ace, Nos3 and Agtr1a genes, along with its in vitro inhibitory activity against ACE, makes it (1) an essential dietary component and (2) a potent adjuvant in treating HT and cardiovascular diseases. This evidence concerns the gene AGTR1 and hematocrit.